The relationship between depression and regional cerebral blood flow in Parkinson’s disease and the effect of selegiline treatment

Acta Neurologica Scandinavica (Impact Factor: 2.47). 06/2011; 124(1):28 - 39. DOI: 10.1111/j.1600-0404.2010.01443.x

ABSTRACT Imamura K, Okayasu N, Nagatsu T. The relationship between depression and regional cerebral blood flow in Parkinson’s disease and the effect of selegiline treatment. Acta Neurol Scand: 2011: 124: 28–39. © 2010 John Wiley & Sons A/S.Objectives –  We examined the relationship between severity of depression in Parkinson’s disease (PD) and regional cerebral blood flow (rCBF) using single photon emission computed tomography (SPECT) and the reaction to levodopa-selegiline combination therapy.Materials and methods –  We evaluated 52 patients with PD and nine age-matched controls with SPECT and the Unified Parkinson’s Disease Rating Scale (UPDRS) part III, Mini-Mental State Examination (MMSE), and Beck Depression Inventory (BDI) to evaluate depression severity and its connection with rCBF. Furthermore, we examined rCBF in patients with PD treated with levodopa with or without selegiline.Results –  A significant fall in rCBF was observed in the bilateral posterior cingulate, hippocampus, and cuneus and the superior parietal and primary visual areas in PD patients with minor depression and in all regions in those with major depression. Elevations in UPDRS part III and BDI scores and falls in MMSE scores were of significantly lower magnitude in the levodopa-selegiline group than in the levodopa group. Whole brain rCBF fell significantly less in the levodopa-selegiline group than in the levodopa group.Conclusions –  These results indicate that selegiline controlled not only worsening of motor function and cognitive function in PD but also aggravation of minor depression, and restrained a fall in whole brain rCBF.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Direct and indirect pathway striatal neurons are known to exert opposing control over motor output. In this review, we discuss a hypothetical extension of this framework, in which direct pathway striatal neurons also mediate reinforcement and reward, and indirect pathway neurons mediate punishment and aversion.
    Physiology 06/2012; 27(3):167-77. · 6.75 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Although medications such as anticancer, antimicrobial, immunomodulatory, neurological or hormonal therapies may have a negative impact on mood, adequate attention was not paid until the withdrawal of rimonabant in 2008. In the present study the authors review full spectrum of currently available medications discussing anxiety and depression as possible adverse effects of treatment. A relatively high risk of depression should always be considered when pharmacotherapy applied, especially if current depressive episodes, positive family history, or neurotic personality traits increasing susceptibility to depressogenic effects. Prior to start of medical treatment, the potential effectiveness of the given drug should be precisely evaluated, and alternative medical and non-medical treatment options should also be carefully considered. In addition, monitoring patients during treatment for signs of depressive or anxious symptoms is necessary. Orv. Hetil., 2013, 154, 1327-1336.
    Orvosi Hetilap 08/2013; 154(34):1327-36.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Depressive disturbances are common in patients with Parkinson's disease (PD) and influence many other clinical aspects of the disease. In addition to causing inherent emotional distress, depressive disorders negatively impact quality of life, motor and cognitive deficits, functional disability, and other psychiatric comorbidities in patients with PD. Knowledge of the pathophysiology of PD depression remains limited. However, clinical studies demonstrate the efficacy of medications and psychotherapies for PD depression, underscoring the importance of their timely detection and concerted management.
    Current Neurology and Neuroscience Reports 12/2013; 13(12):409. · 3.78 Impact Factor


Available from